A5046751920- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Renal and Vascular Pathologies
- Pediatric Urology and Nephrology Studies
- Cancer Genomics and Diagnostics
- Multiple and Secondary Primary Cancers
- Prostate Cancer Diagnosis and Treatment
- Organ Donation and Transplantation
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Economic and Financial Impacts of Cancer
- Ureteral procedures and complications
- Urinary Bladder and Prostate Research
- Cancer Immunotherapy and Biomarkers
- Kidney Stones and Urolithiasis Treatments
- Pelvic floor disorders treatments
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- Urinary Tract Infections Management
- Urological Disorders and Treatments
- Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Urologic and reproductive health conditions
Université d'Angers
2016-2025
Centre Hospitalier Universitaire d'Angers
2016-2025
Lymphoma Study Association
2010-2024
Inserm
2024
Centre National de la Recherche Scientifique
2024
Onco Lille
2024
French Clinical Research Infrastructure Network
2016-2023
Université de Lille
2018
Centre Hospitalier Universitaire de Lille
2018
Groupe de Recherche sur les formes Injectables et les Technologies Associées
2018
Study Type – Therapy (multi‐centre retrospective cohort) Level of Evidence 2b What's known on the subject? and What does study add? Upper urinary tract urothelial carcinomas (UUT‐UCs) are rare tumours. Because aggressive pattern UC, radical nephroureterectomy (RNU) with bladder cuff removal remains ‘gold‐standard’ treatment. However, conservative strategies, such as segmental ureterectomy (SU) or endourological management, have also been developed in patients imperative indications. Some...
Abstract BACKGROUND: Urothelial carcinoma of the upper urinary tract (UUT‐UC) was a rare, aggressive urologic cancer with propensity for multifocality, local recurrence, and metastasis. High‐risk patients had poor outcomes. Because rarity these tumors, randomized clinical trials data regarding adjuvant chemotherapy in locally advanced tumors are currently unavailable. Our objective to assess effect impact potential prognostic factors on survival high‐risk, postsurgical UUT‐UC patients....
Abstract Renal cell carcinoma (RCC) is most often diagnosed at a localized stage, where surgery the standard of care. Existing prognostic scores provide moderate predictive performance, leading to challenges in establishing follow-up recommendations after and selecting patients who could benefit from adjuvant therapy. In this study, we developed model for individual postoperative disease-free survival (DFS) prediction using machine learning (ML) on real-world prospective data. Using French...
There are no validated markers that predict response in metastatic renal cell cancer (RCC) patients treated with sunitinib. We aim to study the impact of single-nucleotide polymorphisms (SNPs) have recently been proposed as predictors outcome anti-VEGF-targeted therapy RCC an independent cohort patients. genotyped 16 key SNPs 10 genes involved sunitinib pharmacokinetics, pharmacodynamics and VEGF-independent angiogenesis clear-cell first-line targeted therapy. Association between SNPs,...
Lithotripsy with holmium:yttrium-aluminum-garnet (Ho:YAG) laser is the current gold standard for treating stones of upper urinary tract (UUT). The recently introduced thulium fiber (TFL) has potential to be more efficient and as safe Ho:YAG.To compare performance complications between Ho:YAG TFL UUT lithotripsy.This was a prospective single-center study 182 patients treated February 2021 2022. In consecutive approach, lithotripsy performed via ureteroscopy 5 mo, then mo.Our primary outcome...
Surgery remains the cornerstone of localized renal cell carcinoma (RCC) care. Pembrolizumab has recently been recommended as a standard care for RCC patients who are at high risk recurrence. Data regarding efficacy ICIs either alone or in combination with VEGF TKIs VTT shrinkage scarce. In framework French kidney cancer research network UroCCR (NCT 03293563), we performed retrospective multicentric European study to evaluate treated metastatic locally advanced (RCC). The primary endpoint was...